CN1658840A - 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型 - Google Patents

用于给予大麻制剂的薄膜形粘膜粘性的给药剂型 Download PDF

Info

Publication number
CN1658840A
CN1658840A CN038137291A CN03813729A CN1658840A CN 1658840 A CN1658840 A CN 1658840A CN 038137291 A CN038137291 A CN 038137291A CN 03813729 A CN03813729 A CN 03813729A CN 1658840 A CN1658840 A CN 1658840A
Authority
CN
China
Prior art keywords
administration
content
agent
group
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN038137291A
Other languages
English (en)
Chinese (zh)
Inventor
沃纳·韦斯林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of CN1658840A publication Critical patent/CN1658840A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN038137291A 2002-06-14 2003-05-08 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型 Pending CN1658840A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10226494.5 2002-06-14
DE10226494A DE10226494A1 (de) 2002-06-14 2002-06-14 Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen

Publications (1)

Publication Number Publication Date
CN1658840A true CN1658840A (zh) 2005-08-24

Family

ID=29719057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN038137291A Pending CN1658840A (zh) 2002-06-14 2003-05-08 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型

Country Status (11)

Country Link
US (1) US20060039959A1 (enExample)
EP (1) EP1513494A2 (enExample)
JP (1) JP4526384B2 (enExample)
CN (1) CN1658840A (enExample)
AU (1) AU2003227735B2 (enExample)
BR (1) BR0311867A (enExample)
CA (1) CA2489106A1 (enExample)
DE (1) DE10226494A1 (enExample)
IL (1) IL165744A0 (enExample)
RU (1) RU2324476C2 (enExample)
WO (1) WO2003105800A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108743571A (zh) * 2018-08-07 2018-11-06 云南汉木森生物科技有限责任公司 预防、治疗癫痫的药物组合物及其制备方法
WO2019034113A1 (zh) * 2017-08-18 2019-02-21 汉义生物科技（北京）有限公司 预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用
WO2019052303A1 (zh) * 2017-09-15 2019-03-21 汉义生物科技（北京）有限公司 含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
CN110200953A (zh) * 2019-06-15 2019-09-06 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
CN111150729A (zh) * 2020-01-16 2020-05-15 全越 一种成膜组合物及其应用
CN111228241A (zh) * 2020-01-16 2020-06-05 全越 一种成膜组合物及其应用
CN114929197A (zh) * 2019-10-16 2022-08-19 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂
CN114945353A (zh) * 2019-10-16 2022-08-26 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂
CN116056738A (zh) * 2020-08-28 2023-05-02 Lts勒曼治疗系统股份公司 粘膜穿孔

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US8242178B2 (en) * 2007-06-18 2012-08-14 University Of South Carolina Use of cannabidiol in the treatment of autoimmune hepatitis
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
MX2011009859A (es) * 2009-04-01 2011-09-29 Colgate Palmolive Co Compuestos derivados de mentol y uso de los mismos como agentes activos orales y sistemicos.
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US9781946B2 (en) * 2010-05-27 2017-10-10 Symrise Ag Flavoring substance-included compounds
RU2453559C1 (ru) * 2010-10-11 2012-06-20 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US9399722B2 (en) 2011-03-31 2016-07-26 The Armor All/Stp Products Company Compositions and methods for treating automotive surfaces
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
WO2014159688A1 (en) 2013-03-14 2014-10-02 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
WO2015069763A2 (en) * 2013-11-05 2015-05-14 First Watersign Llc Sublingual cannabis dosage form and methods of making and using the same
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US10272038B2 (en) * 2013-12-02 2019-04-30 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
US9186386B2 (en) 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing
US10392178B2 (en) * 2014-04-21 2019-08-27 Zen Potion, Inc. Preparing beverages containing cannabinoids using beverage containers with polymer matrices
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
WO2016106329A1 (en) 2014-12-23 2016-06-30 Acelrx Pharmaceuticals, Inc. Systems, devices and methods for dispensing oral transmucosal dosage forms
US20160213027A1 (en) * 2015-01-21 2016-07-28 George Maniatakos Pet food additive
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
KR20180019198A (ko) * 2015-06-22 2018-02-23 존슨 앤드 존슨 컨수머 인코포레이티드 피부에 효과를 제공하기 위한 다층 국소-적용 물품
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US20170112188A1 (en) * 2015-10-22 2017-04-27 John Ostrander Wrapper For Enclosing Smokable Substances
US20170188616A1 (en) * 2015-12-17 2017-07-06 Therabis, Llc Cannabinoid-enriched supplement
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
EP3538078A4 (en) * 2016-11-11 2020-07-08 Bennes, Inc. FORMULATIONS FOR EFFICIENT CANNABINOID DELIVERY
JP2020500220A (ja) 2016-11-15 2020-01-09 クラリア ファーマ ホールディング エービー 医薬製剤
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US20190125660A1 (en) * 2017-10-31 2019-05-02 Calitas Therapeutics, Inc Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
FR3084837B1 (fr) 2018-08-10 2021-10-29 Urgo Rech Innovation Et Developpement Composition filmogene mucoadhesive et son utilisation pour le traitement des douleurs liees aux poussees dentaires
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US11602504B2 (en) * 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
DE102019100483A1 (de) 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm
WO2021055079A1 (en) 2019-09-16 2021-03-25 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
WO2021070120A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US20240325414A1 (en) * 2021-07-22 2024-10-03 Nicoventures Trading Limited Constituent, derivative or extract of cannabis in a water soluble matrix
US11986008B2 (en) 2021-09-01 2024-05-21 David Addington Method of processing cannabis
WO2025116961A1 (en) * 2023-11-27 2025-06-05 J.D.I.P., Llc Cannabis compositions, oral products, and methods of making same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2046773B (en) * 1979-03-21 1983-08-03 Advance Tapes Uk Ltd Gelatinous articles and compositions
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
US5989535A (en) * 1997-08-15 1999-11-23 Soma Technologies Polymeric bioadhesive emulsions and suspensions and methods of treatment
ATE314092T1 (de) * 1997-09-26 2006-01-15 Noven Pharma Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US20030191180A1 (en) * 2000-03-09 2003-10-09 Calvin Ross Pharmaceutical compositions
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US20030017216A1 (en) * 2001-07-23 2003-01-23 Schmidt Robert Gustav Isolation of herbal and cannabinoid medicinal extracts
EP1539069A4 (en) * 2002-05-31 2007-11-14 Univ Mississippi TRANSMUCOSAL DELIVERY OF CANNABINOIDS

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019034113A1 (zh) * 2017-08-18 2019-02-21 汉义生物科技（北京）有限公司 预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用
CN109394836A (zh) * 2017-08-18 2019-03-01 汉义生物科技（北京）有限公司 一种预防和/或缓解痛经的大麻纤维及其在卫生用品中的应用
WO2019052303A1 (zh) * 2017-09-15 2019-03-21 汉义生物科技（北京）有限公司 含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技（北京）有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
CN108743571A (zh) * 2018-08-07 2018-11-06 云南汉木森生物科技有限责任公司 预防、治疗癫痫的药物组合物及其制备方法
CN108743571B (zh) * 2018-08-07 2020-10-02 云南汉木森生物科技有限责任公司 预防、治疗癫痫的药物组合物及其制备方法
CN110200953A (zh) * 2019-06-15 2019-09-06 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
CN114929197A (zh) * 2019-10-16 2022-08-19 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂
CN114945353A (zh) * 2019-10-16 2022-08-26 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂
CN111150729A (zh) * 2020-01-16 2020-05-15 全越 一种成膜组合物及其应用
CN111150729B (zh) * 2020-01-16 2021-02-12 全越 一种成膜组合物及其应用
CN111228241A (zh) * 2020-01-16 2020-06-05 全越 一种成膜组合物及其应用
CN111228241B (zh) * 2020-01-16 2023-08-04 全越 一种成膜组合物及其应用
CN116056738A (zh) * 2020-08-28 2023-05-02 Lts勒曼治疗系统股份公司 粘膜穿孔

Also Published As

Publication number Publication date
AU2003227735B2 (en) 2009-07-09
RU2324476C2 (ru) 2008-05-20
IL165744A0 (en) 2006-01-15
WO2003105800A2 (de) 2003-12-24
WO2003105800A3 (de) 2004-12-09
EP1513494A2 (de) 2005-03-16
JP4526384B2 (ja) 2010-08-18
RU2005100953A (ru) 2005-09-20
JP2005533780A (ja) 2005-11-10
DE10226494A1 (de) 2004-01-08
AU2003227735A1 (en) 2003-12-31
US20060039959A1 (en) 2006-02-23
CA2489106A1 (en) 2003-12-24
BR0311867A (pt) 2005-03-15

Similar Documents

Publication Publication Date Title
CN1658840A (zh) 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型
JP6198370B2 (ja) 経口投与剤形
JP2005533780A5 (enExample)
WO2007096906A2 (en) Novel buccoadhesive compositions and process of preparation thereof
JP2013079265A (ja) 薬物置換療法のためのブプレノルフィンウェハー
CA3216889A1 (en) Novel n,n-dimethyltryptamine compositions and methods
CN114901264A (zh) 药物制剂
JP2009521433A (ja) 低粘度アルギン酸塩含有水溶性薄膜
CN1812765B (zh) 具有降低的粘膜刺激的经粘膜给药剂型
Gijare et al. Orodispersible films: a systematic patent review
TW202019394A (zh) 供置入口腔之劑型
JP2009539892A (ja) 組み合わせ抗うつ薬ウェーハ
TW200306804A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
US20090291123A1 (en) Opioid Combination Wafer
US12383591B2 (en) Chewing gum containing synergistic medicinal compounds
CN1886137A (zh) 脱氧鸭嘴花碱的口服制剂及其应用
KR20050021003A (ko) 대마 활성 성분의 투여용 필름 형상의 점막접착성 투여 제형
CA3239914A1 (en) Oral cannabinoid compositions and methods for treating neurological diseases and disorders
CN1223338C (zh) 盐酸西替利嗪凝胶剂
CN115025125A (zh) 一种用于治疗口腔溃疡的药物组合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050824